Luke Combs shared how his physical appearance has affected his mindset throughout his career as one of country music’s most successful artists.

It’s been a topsy-turvy week for Novo Nordisk, makers of the popular weight loss drugs Ozempic and Wegovy. Fresh off the heels of a disappointing trial for one experimental drug, the company has just ...

Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year. Starting on Jan. 1, ...

Feb 10 (Reuters) - U.S.-based Kailera Therapeutics and its partner Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab said on Tuesday their experimental oral obesity drug helped patients lose ...

In October of last year, Kailera Therapeutics unveiled a whopping $600 million series B financing raised to fund a phase 3 trial of its injected, dual-agonist obesity drug ribupatide. Four months ...

COPENHAGEN, Denmark — Novo Nordisk sued Hims and Hers Health on Monday over alleged patent infringement after the U.S. telehealth firm launched, then canceled, a $49 copy of Novo's weight-loss pill ...

Hims & Hers Health stock fell Monday after Novo Nordisk said it had filed a lawsuit to ban the online drug retailer from offering knockoff versions of Novo’s Ozempic and Wegovy weight-loss pills.

Hims & Hers caused a firestorm last week when it revealed that it planned to launch a knockoff version of Novo Nordisk's new oral weight loss medicine. But the reaction to the move has caused the ...

Shares in Wegovy and Ozempic maker Novo Nordisk rose after Hims & Hers said it would not offer a copycat version of the Danish drugmaker's weight-loss pill. In afternoon European trade, shares were up ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy — two days after it announced the new drug and one day after the Food and Drug Administration ...